Biotikon completely dispenses with the use of release agents and lubricants in their capsule production
Observed in pilot human work A 2025 IV infusion pilot of BPC-157 in two adults at 10 mg and 20 mg reported no adverse effects on cardiac, hepatic, renal, thyroid, or glucose biomarkers (Lee et al., Alternative Therapies in Health and Medicine, 2025)
When used at night, it continues to offer antioxidant protection while skin is in its resting and repair stages, working to boost radiance for skin that is visibly more radiant during the day
There are various types of mutations, including chromosomal, point, frameshift, and expansion mutations